Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High – Time to Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $34.34 and last traded at $33.73, with a volume of 62141 shares. The stock had previously closed at $32.53.

Wall Street Analyst Weigh In

MAZE has been the topic of a number of research reports. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price target on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. Wedbush upped their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Guggenheim raised their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Finally, Raymond James Financial started coverage on Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $38.57.

Maze Therapeutics Stock Down 0.9%

The company’s 50 day simple moving average is $28.24 and its 200-day simple moving average is $18.46. The firm has a market cap of $1.60 billion and a P/E ratio of -1.59.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insiders Place Their Bets

In other news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. grew its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the third quarter worth approximately $52,000. CWM LLC purchased a new position in Maze Therapeutics during the 2nd quarter worth $28,000. Finally, New York State Common Retirement Fund purchased a new position in Maze Therapeutics during the 1st quarter worth $25,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.